Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin
Diabetes, Obesity and Metabolism Jan 26, 2018
Polidori D, et al. - This study was conducted to assess the intra- and inter-subject variability for increases in serum ketone bodies in Japanese patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin 100 or 200 mg. Compared to changes in other metabolic measures, increases in serum ketone bodies with canagliflozin were greater and more variable in Japanese subjects with T2DM.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
